Castle Biosciences, Inc. beat EPS estimates 46% of the time across 13 reported quarters (6 beats, 7 misses), averaging -11.1% versus consensus. Data sourced from SEC EDGAR.
| Quarter | EPS Estimate | EPS Actual | Surprise | Result | Call |
|---|---|---|---|---|---|
| Q2 FY26 | not reported | $-0.07 | not reported | not reported | Q2 FY26 call |
| Q1 FY26 | $-0.56 | $-0.49 | +12.5% | Beat | |
| Q4 FY25 | not reported | $-0.08 | not reported | not reported | Q4 FY25 call |
| Q3 FY25 | not reported | $-0.02 | not reported | not reported | |
| Q2 FY25 | not reported | $0.15 | not reported | not reported | |
| Q1 FY25 | not reported | $-0.20 | not reported | not reported | |
| Q4 FY24 | not reported | $0.32 | not reported | not reported | |
| Q3 FY24 | not reported | $0.08 | not reported | not reported | |
| Q2 FY24 | not reported | $0.31 | not reported | not reported | |
| Q1 FY24 | not reported | $-0.09 | not reported | not reported | |
| Q4 FY23 | not reported | $-0.10 | not reported | not reported | |
| Q3 FY23 | not reported | $-0.26 | not reported | not reported |
Back to CSTL overview · CSTL holders · CSTL KPIs
Data sourced from U.S. SEC EDGAR filings. Not personalized investment advice.